[1]
|
Jia M, Zheng R, Zhang S, et al. Female breast cancer incidence and mortality in 2011, China[J]. J Thorac Dis, 2015, 7(7):1221-1226. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgazyj201603006
|
[2]
|
Zuo TT, Zheng RS, Zeng HM, et al. Female breast cancer incidence and mortality in China, 2013[J]. Thorac Cancer, 2017, 8(3):214-218. doi: 10.1111/tca.2017.8.issue-3
|
[3]
|
陈万青, 郑荣寿, 曾红梅, 等.1989-2008年中国恶性肿瘤发病趋势分析[J].中华肿瘤杂志, 2012, 34(7):517-524. doi: 10.3760/cma.j.issn.0253-3766.2012.07.010
|
[4]
|
Zeng H, Zheng R, Zhang S, et al. Incidence and mortality of female breast cancer in China, 2009[J]. Thorac Cancer, 2013, 4(4):400-404. doi: 10.1111/tca.2013.4.issue-4
|
[5]
|
Zeng H, Zheng R, Zhang S, et al. Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries[J]. J Thorac Dis, 2014, 6(5):466-470. http://cn.bing.com/academic/profile?id=5c555483dc14014b0b9aced03848fa24&encoded=0&v=paper_preview&mkt=zh-cn
|
[6]
|
Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1):1-11. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgazyj201601001
|
[7]
|
李贺, 郑荣寿, 张思维, 等.2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3):166-171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002
|
[8]
|
孙可欣, 郑荣寿, 顾秀瑛, 等.2000-2014年中国肿瘤登记地区女性乳腺癌发病趋势及年龄变化情况分析[J].中华预防医学杂志, 2018, 52 (6):567-572. doi: 10.3760/cma.j.issn.0253-9624.2018.06.003
|
[9]
|
Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8):1921-1930. http://cn.bing.com/academic/profile?id=484e070786366d08b99f8be681bdd397&encoded=0&v=paper_preview&mkt=zh-cn
|
[10]
|
Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4):271-289. doi: 10.3322/caac.v66.4
|
[11]
|
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. doi: 10.3322/caac.21262
|
[12]
|
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-386. doi: 10.1002/ijc.29210
|
[13]
|
Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1.22 million Chinese females and different cancer patterns between urban and rural women[J]. Sci Rep, 2016, 6:39459. doi: 10.1038/srep39459
|
[14]
|
Shapiro S. Periodic screening for breast cancer: the HIP randomized controlled trial. Health insurance plan[J]. J Natl Cancer Inst Monogr, 1997, 22:27-30. http://cn.bing.com/academic/profile?id=532adc0e7ec2c6599f5f5cfca322789c&encoded=0&v=paper_preview&mkt=zh-cn
|
[15]
|
Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the health insurance plan clinical trial[J]. J Natl Cancer Inst, 1988, 80(14):1125-1132. doi: 10.1093/jnci/80.14.1125
|
[16]
|
Habbema JD, van Oortmarssen GJ, van Putten DJ, et al. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the health insurance plan of greater New York study[J]. J Natl Cancer Inst, 1986, 77(2):317-320. http://cn.bing.com/academic/profile?id=8bbcabb28cb78f7a36b8b99701b213af&encoded=0&v=paper_preview&mkt=zh-cn
|
[17]
|
Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality[J]. J Natl Cancer Inst, 1982, 69(2): 349-355. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=HighWire000005668366
|
[18]
|
Miller AB, Wall C, Baines CJ, et al. Twenty-five year follow-up for breast cancer incidence and mortality of the Canadian national breast screening study: randomised screening trial[J]. BMJ, 2014, 348:g366. doi: 10.1136/bmj.g366
|
[19]
|
Miller AB, To T, Baines CJ, et al. The Canadian national breast screening study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years[J]. Ann Intern Med, 2002, 137(5 Part 1):305-312. http://cn.bing.com/academic/profile?id=98c37eeca41f206b9fdab574ac01aa5c&encoded=0&v=paper_preview&mkt=zh-cn
|
[20]
|
Miller AB, To T, Baines CJ, et al. Canadian national breast screening study-2: 13-year results of a randomized trial in women aged 50-59 years[J]. J Natl Cancer Inst, 2000, 92(18):1490-1499. doi: 10.1093/jnci/92.18.1490
|
[21]
|
Miller AB, Baines CJ, To T, et al. Canadian national breast screening study: 1. Breast cancer detection and death rates among women aged 40 to 49 years[J]. CMAJ, 1992, 147(10):1459-1476. http://cn.bing.com/academic/profile?id=baa9059f6038a5338c904e55545d46ff&encoded=0&v=paper_preview&mkt=zh-cn
|
[22]
|
Miller AB, Baines CJ, To T, et al. Canadian national breast screening study: 2. Breast cancer detection and death rates among women aged 50 to 59 years[J]. CMAJ, 1992, 147(10):1477-1488. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1336544/
|
[23]
|
Moss SM, Wale C, Smith R, et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1123-1132. doi: 10.1016/S1470-2045(15)00128-X
|
[24]
|
Johns LE, Moss SM. False-positive results in the randomized controlled trial of mammographic screening from age 40 (" Age" trial)[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(11):2758-2764. doi: 10.1158/1055-9965.EPI-10-0623
|
[25]
|
Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial[J]. Lancet, 2006, 368(9552):2053-2060. doi: 10.1016/S0140-6736(06)69834-6
|
[26]
|
Frisell J, Lidbrink E, Hellströ m L, et al. Follow-up after 11 years-update of mortality results in the Stockholm mammographic screening trial[J]. Breast Cancer Res Treat, 1997, 45(3):263-270. doi: 10.1023/A:1005872617944
|
[27]
|
Frisell J, Lidbrink E. The Stockholm mammographic screening trial: risks and benefits in age group 40-49 years[J]. J Natl Cancer Inst Monogr, 1997, 22:49-51. http://cn.bing.com/academic/profile?id=6749aacad102fb1d647c6cc1bf115e81&encoded=0&v=paper_preview&mkt=zh-cn
|
[28]
|
Frisell J, Eklund G, Hellstrom L, et al. Randomized study of mammography screening-preliminary report on mortality in the Stockholm trial[J]. Breast Cancer Res Treat, 1991, 18(1):49-56. http://cn.bing.com/academic/profile?id=0f09ba5ca282ae595b91742c2cd47c7b&encoded=0&v=paper_preview&mkt=zh-cn
|
[29]
|
Frisell J, Glas U, Hellstrom L, et al. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons[J]. Breast Cancer Res Treat, 1986, 8(1):45-54. http://cn.bing.com/academic/profile?id=2416b0c65909a2bc847feb55074f3cc6&encoded=0&v=paper_preview&mkt=zh-cn
|
[30]
|
Zackrisson S, Andersson I, Janzon L, et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study[J]. BMJ, 2006, 332(7543):689-692. doi: 10.1136/bmj.38764.572569.7C
|
[31]
|
Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö mammographic screening program[J]. J Natl Cancer Inst Monogr, 1997, 22:63-67. https://www.researchgate.net/publication/13576591_Reduced_Breast_Cancer_Mortality_in_Women_Under_Age_50_Updated_Results_From_the_Malmo_Mammographic_Screening_Program
|
[32]
|
Ikeda DM, Andersson I, Wattsgaå rd C, et al. Interval carcinomas in the Malmö mammographic screening trial: radiographic appearance and prognostic considerations[J]. AJR Am J Roentgenol, 1992, 159(2):287- 294. doi: 10.2214/ajr.159.2.1632342
|
[33]
|
Tabár L, Duffy S. Malmö mammographic screening trial[J]. BMJ, 1989, 298(6665):48-49. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_1410836
|
[34]
|
Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial[J]. BMJ, 1988, 297(6654):943-948. doi: 10.1136/bmj.297.6654.943
|
[35]
|
Andersson I, Janzon L, Sigfusson BF. Mammographic breast cancer screening-a randomized trial in Malmö, Sweden[J]. Maturitas, 1985, 7(1):21-29. doi: 10.1016/0378-5122(85)90031-3
|
[36]
|
Bjurstam N, Bjö rneld L, Warwick J, et al. The Gothenburg breast screening trial[J]. Cancer, 2003, 97(10): 2387-2396. doi: 10.1002/cncr.v97:10
|
[37]
|
Miller AB, Baines CJ, To T. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization[J]. Cancer, 1998, 83(1):186-190. doi: 10.1002/(ISSN)1097-0142
|
[38]
|
Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization[J]. Cancer, 1997, 80(11):2091-2099. doi: 10.1002/(ISSN)1097-0142
|
[39]
|
Bjurstam N, Bjö rneld L, Duffy SW, et al. The Gothenburg breast cancer screening trial: preliminary results on breast cancer mortality for women aged 39-49[J]. J Natl Cancer Inst Monogr, 1997, 22:53-55. http://cn.bing.com/academic/profile?id=5581b4d7fef9495105ad1a714ed38956&encoded=0&v=paper_preview&mkt=zh-cn
|
[40]
|
Tabar L, Chen TH, Hsu CY, et al. Evaluation issues in the Swedish twocounty trial of breast cancer screening: an historical review[J]. J Med Screen, 2017, 24(1):27-33. http://cn.bing.com/academic/profile?id=80aa332f66b3bce76680954481ca0d23&encoded=0&v=paper_preview&mkt=zh-cn
|
[41]
|
Yen AM, Duffy SW, Chen TH, et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish two-county trial of mammographic screening[J]. Cancer, 2012, 118(23):5728-5732. doi: 10.1002/cncr.v118.23
|
[42]
|
Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades [J]. Radiology, 2011, 260(3):658-663. doi: 10.1148/radiol.11110469
|
[43]
|
Duffy SW, Tabar L, Vitak B, et al. The Swedish two- county trial of mammographic screening: cluster randomisation and end point evaluation[J]. Ann Oncol, 2003, 14(8):1196-1198. doi: 10.1093/annonc/mdg322
|
[44]
|
Nyströ m L, Andersson I, Bjurstam N, et al. Long- term effects of mammography screening: updated overview of the Swedish randomised trials[J]. Lancet, 2002, 359(9310):909-919. doi: 10.1016/S0140-6736(02)08020-0
|
[45]
|
Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish two-county trial[J]. Cancer, 1995, 75(10):2507-2517. doi: 10.1002/1097-0142%2819950515%2975%3A10%3C2507%3A%3AAID-CNCR2820751017%3E3.0.CO%3B2-H#references-section
|
[46]
|
Wang Q, Li J, Zheng S, et al. Breast cancer stage at diagnosis and areabased socioeconomic status: a multicenter 10- year retrospective clinical epidemiological study in China[J]. BMC Cancer, 2012, 12(1):122. doi: 10.1186/1471-2407-12-122
|
[47]
|
Zheng S, Bai JQ, Li J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999- 2008: a national- wide multicenter cross-sectional image over 10 years[J]. Int J Cancer, 2012, 131(11):2622-2631. doi: 10.1002/ijc.v131.11
|
[48]
|
李卫芹, 李蓉, 刘佩芳, 等.中国乳腺癌筛查模式探讨[J].中华流行病学杂志, 2016, 37(7):1039-1043. doi: 10.3760/cma.j.issn.0254-6450.2016.07.026
|
[49]
|
Corsetti V, Houssami N, Ghirardi M, et al. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1-year follow-up[J]. Eur J Cancer, 2011, 47(7):1021-1026. doi: 10.1016/j.ejca.2010.12.002
|
[50]
|
Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial[J]. J Clin Oncol, 2016, 34(16)1882-1888. doi: 10.1200/JCO.2015.63.4147
|
[51]
|
Weigert J, Steenbergen S. The connecticut experiments second year: ultrasound in the screening of women with dense breasts[J]. Breast J, 2015, 21(2):175-180. doi: 10.1111/tbj.12386
|
[52]
|
Moon HJ, Jung I, Park SJ, et al. Comparison of cancer yields and diagnostic performance of screening mammography vs. supplemental screening ultrasound in 4 394 women with average risk for breast cancer[J]. Ultraschall Med, 2015, 36(3):255-263. https://yonsei.pure.elsevier.com/en/publications/comparison-of-cancer-yields-and-diagnostic-performance-of-screeni
|
[53]
|
Parris T, Wakefield D, Frimmer H. Real world performance of screening breast ultrasound following enactment of Connecticut Bill 458[J]. Breast J, 2013, 19(1):64-70. doi: 10.1111/tbj.12053
|
[54]
|
Girardi V, Tonegutti M, Ciatto S, et al. Breast ultrasound in 22, 131 asymptomatic women with negative mammography[J]. Breast, 2013, 22(5):806-809. doi: 10.1016/j.breast.2013.02.010
|
[55]
|
Leong LC, Gogna A, Pant R, et al. Supplementary breast ultrasound screening in Asian women with negative but dense mammograms-a pilot study[J]. Ann Acad Med Singapore, 2012, 41(10):432-439. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=af48acca113a8b8949be9acbf8cae175
|
[56]
|
Youk JH, Kim EK, Kim MJ, et al. Performance of hand-held whole-breast ultrasound based on BI- RADS in women with mammographically negative dense breast[J]. Eur Radiol, 2011, 21(4):667-675. doi: 10.1007/s00330-010-1955-8
|
[57]
|
Brancato B, Bonardi R, Catarzi S, et al. Negligible advantages and excess costs of routine addition of breast ultrasonography to mammography in dense breasts[J]. Tumori, 2007, 93(6):562-566. doi: 10.1177/030089160709300608
|
[58]
|
Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan strategic anti-cancer randomized trial (J-START): a randomised controlled trial[J]. Lancet, 2016, 387(10016):341-348. doi: 10.1016/S0140-6736(15)00774-6
|
[59]
|
Brem RF, Tabar L, Duffy SW, et al. Assessing improvement in detection of breast cancer with three- dimensional automated breast US in women with dense breast tissue: the SomoInsight study[J]. Radiology, 2015, 274(3):663-673. doi: 10.1148/radiol.14132832
|
[60]
|
Berg WA, Bandos AI, Mendelson EB, et al. Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6 666[J]. J Natl Cancer Inst, 2015, 108(4):pii367. http://cn.bing.com/academic/profile?id=522bf78b564ea85d0c48a2a0ba88de37&encoded=0&v=paper_preview&mkt=zh-cn
|
[61]
|
Kelly KM, Dean J, Comulada WS, et al. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts[J]. Eur Radiol, 2010, 20(3):734-742. doi: 10.1007/s00330-009-1588-y
|
[62]
|
Wilczek B, Wilczek HE, Rasouliyan L, et al. Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: report from a hospital-based, high-volume, single-center breast cancer screening program[J]. Eur J Radiol, 2016, 85(9):1554-1563. doi: 10.1016/j.ejrad.2016.06.004
|
[63]
|
Venturini E, Losio C, Panizza P, et al. Tailored breast cancer screening program with microdose mammography, US, and MR imaging: shortterm results of a pilot study in 40-49-year-old women[J]. Radiology, 2013, 268(2):347-355. doi: 10.1148/radiol.13122278
|
[64]
|
Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts[J]. Clin Imaging, 2013, 37(3):480-486. doi: 10.1016/j.clinimag.2012.09.018
|
[65]
|
Dong H, Huang Y, Song F, et al. Improved performance of adjunctive ultrasonography after mammography screening for breast cancer among Chinese females[J]. Clin Breast Cancer, 2018, 18(3): e353-e361. doi: 10.1016/j.clbc.2017.07.014
|
[66]
|
Shen S, Zhou Y, Xu Y, et al. A multi-centre randomised trial comparing ultrasound vs. mammography for screening breast cancer in high-risk Chinese women[J]. Br J Cancer, 2015, 112(6):998-1004. doi: 10.1038/bjc.2015.33
|
[67]
|
Tozaki M, Kuroki Y, Kikuchi M, et al. The Japanese breast cancer society clinical practice guidelines for screening and imaging diagnosis of breast cancer, 2015 edition[J]. Breast Cancer, 2016, 23(3):357-366. doi: 10.1007/s12282-016-0674-7
|
[68]
|
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017版)[J].中国癌症杂志, 2017, 27(9):695-760. http://www.cnki.com.cn/Article/CJFDTotal-ZGAZ200705015.htm
|
[69]
|
Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India[J]. J Natl Cancer Inst, 2011, 103(19):1476-1480. doi: 10.1093/jnci/djr304
|
[70]
|
Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast- cancer screening (STORM): a prospective comparison study[J]. Lancet Oncol, 2013, 14(7):583-589. doi: 10.1016/S1470-2045(13)70134-7
|
[71]
|
Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk[J]. JAMA, 2012, 307(13):1394-1404. doi: 10.1001/jama.2012.388
|
[72]
|
Kuhl CK, Schrading S, Strobel K, et al. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI[J]. J Clin Oncol, 2014, 32(22):2304-2310. doi: 10.1200/JCO.2013.52.5386
|
[73]
|
Kriege M, Brekelmans CT, Obdeijn IM, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer[J]. Breast Cancer Res Treat, 2006, 100(1):109-119. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=89abb88c8d9d2ce6d8de635ad8577562
|
[74]
|
Li JY, Jing R, Wei H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer [J]. Int J Cancer, 2019, 144(2):281-289. doi: 10.1002/ijc.v144.2
|
[75]
|
Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer[J]. Breast Cancer Res Treat, 2016, 158(3):455-462. doi: 10.1007/s10549-016-3902-0
|
[76]
|
Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2, 991 patients and 1, 043 controls by next-generation sequencing[J]. Int J Cancer, 2017, 141(1):129-142. doi: 10.1002/ijc.v141.1
|
[77]
|
Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations[J]. Breast Cancer Res Treat, 2016, 156(3): 441-445. doi: 10.1007/s10549-016-3766-3
|
[78]
|
BRCA数据解读中国专家共识编写组.BRCA数据解读中国专家共识[J].中华病理学杂志, 2017, 46(5):293-297. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx201705002
|
[79]
|
Cuzick J, Forbes J, Edwards R, et al. First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial [J]. Lancet, 2002, 360(9336):817-824. doi: 10.1016/S0140-6736(02)09962-2
|
[80]
|
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study[J]. J Natl Cancer Inst, 1998, 90(18):1371-1388. doi: 10.1093/jnci/90.18.1371
|
[81]
|
Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial[J]. Lancet, 1998, 352(9122):98-101. doi: 10.1016/S0140-6736(98)85012-5
|
[82]
|
Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study[J]. Lancet, 1998, 352(9122):93-97. doi: 10.1016/S0140-6736(98)85011-3
|
[83]
|
Goss PE, Ingle JN, Alés-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N Engl J Med, 2011, 364(25): 2381-2391. doi: 10.1056/NEJMoa1103507
|
[84]
|
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-Ⅱ): an international, double-blind, randomised placebo-controlled trial[J]. Lancet, 2014, 383 (9922):1041-1048. doi: 10.1016/S0140-6736(13)62292-8
|
[85]
|
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4. 2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(3):310-320. doi: 10.6004/jnccn.2018.0012
|
[86]
|
Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers[J]. J Natl Cancer Inst, 2001, 93(21):1633-1637. doi: 10.1093/jnci/93.21.1633
|
[87]
|
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers[J]. J Natl Cancer Inst, 2009, 101(2): 80-87. doi: 10.1093/jnci/djn442
|
[88]
|
Wong IO, Kuntz KM, Cowling BJ, et al. Cost effectiveness of mammography screening for Chinese women[J]. Cancer, 2007, 110(4):885- 895. doi: 10.1002/(ISSN)1097-0142
|